Anna Nijdam Sells 5,501 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anna Nijdam sold 5,501 shares of the business’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $30.74, for a total transaction of $169,100.74. Following the sale, the insider owned 48,945 shares of the company’s stock, valued at approximately $1,504,569.30. This represents a 10.10% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Anna Nijdam also recently made the following trade(s):

• On Thursday, May 21st, Anna Nijdam sold 1,829 shares of Pharvaris stock. The stock was sold at an average price of $30.60, for a total value of $55,967.40.

Pharvaris Price Performance

Pharvaris stock traded up $0.20 during mid-day trading on Tuesday, reaching $29.88. 191,721 shares of the stock traded hands, compared to its average volume of 227,155. The stock has a market capitalization of $1.95 billion, a PE ratio of -9.40 and a beta of -2.34. The business’s 50-day moving average is $28.52 and its 200-day moving average is $26.90. Pharvaris N.V. has a 12-month low of $15.46 and a 12-month high of $33.33.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.82) by $0.12. Equities analysts anticipate that Pharvaris N.V. will post -3.25 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Royal Bank Of Canada reduced their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. UBS Group set a $74.00 price target on Pharvaris in a research report on Wednesday, May 13th. Wall Street Zen raised Pharvaris from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. Citizens Jmp reduced their target price on shares of Pharvaris from $75.00 to $74.00 and set a “market outperform” rating for the company in a report on Wednesday, May 13th. Finally, Citigroup reaffirmed a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Pharvaris presently has an average rating of “Moderate Buy” and a consensus target price of $49.18.

Institutional Trading of Pharvaris

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. GF Fund Management CO. LTD. bought a new position in Pharvaris in the 4th quarter worth approximately $35,000. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock worth $59,000 after buying an additional 783 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Pharvaris during the third quarter worth $75,000. Barclays PLC purchased a new position in Pharvaris during the fourth quarter valued at $77,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Pharvaris in the 4th quarter valued at $86,000.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.